Leishmaniasis, Visceral
Recent clinical, regulatory, research and industry developments relating to this disease.
Immune response to viscerotropic <i>Leishmania</i>: a comprehensive review.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes4
- Disability-Adjusted Life Years1
- Global Burden of Disease1
- Leishmaniasis, Visceral1
- Neglected Diseases1
Leading journals3
- BMJ (Clinical research ed.)1
- Frontiers in immunology1
- Transactions of the Royal Society of Tropical Medicine and Hygiene1
Leading researchers8
- Azzari C1
- Chiappini E1
- Desjeux P1
- Djirmay AG1
- Fall IS1
- Galli L1
- Li WH1
- Lodi L1
Affiliations (unnormalised)5
- Meyer Children's Hospital IRCCS1
- National Institute of Parasitic Diseases at Chinese Center for Disease Control and Prevention1
- NHC Key Laboratory of Tropical Disease Control1
- One Health Center1
- University of Florence1
Reference
Authoritative identity, definition & identifiers.
A chronic disease caused by LEISHMANIA DONOVANI and transmitted by the bite of several sandflies of the genera Phlebotomus and Lutzomyia. It is commonly characterized by fever, chills, vomiting, anemia, hepatosplenomegaly, leukopenia, hypergammaglobulinemia, emaciation, and an earth-gray color of the skin. The disease is classified into three main types according to geographic distribution: Indian, Mediterranean (or infantile), and African.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.